PATENT CLAIM ANALYSIS

Application Number: 16080196
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "001890"]

Abstract:
The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.

Claim (Index 10):
A method for preparing a radiolabeled compound; said method comprising the steps of:\n reacting radiolabeled with a compound of formula (Ib) and isolating the resulting compound of formula (I)

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.55435
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15140572', '15200346', '15529333', '16062399', '15186795']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7122692623737831
- 35 USC 102 Novelty (BERT): 0.5152021004299072
- Combined Prediction Score: 0.6925625461793955
- Mean Citation Score: 223.16952200000003
- Max Citation Score: 231.76335
- Similarity Product: 122.52328031399846

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test